右丙亚胺预防乳腺癌患者蒽环类药物化疗所致心脏毒性的效果和经济性系统综述  

Systematic review on the prevention effect of dexrazoxane on cardiotoxicity and its economic evaluation in breast cancer patients with anthracycline-based chemotherapy

作　　者：郭婉婕[1] 官海静[2] 马爱霞[1] 

机构地区：[1]中国药科大学国际医药商学院,南京211198 [2]北京大学中国卫生经济研究中心,北京100080

出　　处：《中国新药杂志》2017年第11期1328-1334,共7页Chinese Journal of New Drugs

摘　　要：目的:对右丙亚胺预防乳腺癌患者化疗所致心脏毒性的效果和经济性进行系统综述。方法:计算机检索Pubmed,Science Direct,The Cochrane Library,EMbase,中国知网数据库、万方数据库和维普中文科技期刊数据库,系统检索国内外公开发表的蒽环类药物联用右丙亚胺治疗乳腺癌的临床研究和经济学研究,并对其进行质量评价。结果:最终纳入9篇文献,包含6篇临床文献(7项随机对照试验)和3篇药物经济学文献。7项随机对照试验中,联用右丙亚胺治疗的患者出现心脏毒性和充血性心力衰竭的概率均显著低于单用蒽环类药物的患者。3篇药物经济学研究中,2篇研究显示相比单用蒽环类药物,蒽环类药物联用右丙亚胺治疗乳腺癌具有经济性,另1篇研究未指出其是否具有经济性。结论:右丙亚胺对于接受蒽环类药物化疗的乳腺癌患者有显著的心脏保护作用。但是,蒽环类药物联用右丙亚胺治疗乳腺癌的药物经济学研究极其有限,需要更多研究来验证。Objective： To systematically review the prevention effect of dexrazoxane on cardiotoxicity and its economic evaluation in breast cancer patients with anthracycline-based chemotherapy. Methods： We searched databases including Pubmed, Science Direct, The Cochrane Library, EMbase, CNKI, WanFang Data and VIP, to systematically search published studies involving the prevention effect of dexrazoxane on cardiotoxicity and its economic evaluation in breast cancer patients with anthracycline-based chemotherapy, and assessed the quality of these studies. Results： A total of 9 studies were included, involving 6 clinical studies （7 clinical trials） and 3 economic evaluation studies. Dexrazoxane significantly reduced the occurrence of cardiac event and congestive heart failure in 7 clinical trials. Among 3 economic evaluation studies, 2 studies showed the economics of dexrazoxane combined with anthracycline. Another study did not explicitly indicate its conclusion. Conclusion： Dexrazoxane has the significant cardioprotection in breast cancer patients treated with anthracycline-based chemotherapy. However, the studies of economic evaluation are extremely limited, and more studies are needed to confirm its economics.

关 键 词：右丙亚胺 乳腺癌 蒽环类药物 心脏毒性 

分 类 号：R979.1[医药卫生—药品]